Robert Alarcón Cedeño

Dr. Robert Alarcón Cedeño

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Open access
Andrea ScottiAndrea Scotti
Andrea Scotti
SBSara Baggio
Sara Baggio
MPMatteo Pagnesi
Matteo Pagnesi
MBMarco Barbanti
Marco Barbanti
MAMarianna Adamo
Marianna Adamo
OIon behalf of the NEOPRO and NEOPRO-2 Investigators‡
on behalf of the NEOPRO and NEOPRO-2 Investigators‡
Background: In recent years, transcatheter aortic valve replacement (TAVR) techniques and technology have continuously improved. Data regarding the impact of these advancements on outcomes in large real-world settings are still limited. The aim of this study was to investigate temporal trends and assess contemporary outcomes after TAVR with Evolut PRO/PRO+ supra-annular self-expanding valves. Methods: This study included patients enrolled in the multicenter NEOPRO (A Multicenter Comparison of Acurate NEO Versus Evolut PRO Transcatheter Heart Valves) and NEOPRO-2 (A Multicenter Comparison of ACURATE NEO2 Versus Evolut PRO/PRO+ Transcatheter Heart Valves 2) registries who underwent transfemoral TAVR with Evolut PRO/PRO+. Procedural dates (August 2017 through November 2021) were stratified in quartiles (Q) and used to investigate temporal trends in TAVR outcomes. Predischarge, 30-day Valve Academic Research Consortium-3 defined, and 1-year outcomes were evaluated. Results: In total, 1616 patients from 28 centers were included. Over time, patients had lower Society of Thoracic Surgeon-Predicted Risk of Mortality score (Q1–4, 4.1% [2.8–6.3%], 3.7% [2.6–5.3%], 3.3% [2.4–4.9%], 2.9% [2.2–4.3%]; P <0.001) and more moderate or heavy valve calcification (Q1–4, 80%, 80%, 82%, 88%; P =0.038). Overall Valve Academic Research Consortium-3 technical success was 94.1%, with 30-day and 1-year all-cause mortality of 2.4% and 10%, respectively. Throughout the study period, procedures were associated with higher rates of 30-day device success (Q1–4, 81.2%, 82.2%, 82.0%, 88.0%; Cochran-Armitage P =0.023) and early safety (Q1–4, 66.8%, 67.5%, 74.0%, 77.6%; Cochran-Armitage P <0.001), with fewer permanent pacemaker implantations (Q1–4: 15.3%, 20.0%, 12.1%, 11.6%; Cochran-Armitage P =0.023) and residual mild or greater paravalvular leaks (Q1–4, 50.4%, 42.1%, 36.5%, 35.8%; Cochran-Armitage P <0.001). Conclusions: TAVR with Evolut PRO/PRO+ self-expanding valve is safe and effective. Despite the treatment of heavier calcified anatomies, procedural outcomes are improving over time with less need for pacemaker implantation and less significant paravalvular leaks.

20 December 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MBManuel Barreiro-Pérez
Manuel Barreiro-Pérez
BCBerenice Caneiro-Queija
Berenice Caneiro-Queija
LPLuís Puga
Luís Puga
RGRocío Gonzalez-Ferreiro
Rocío Gonzalez-Ferreiro
RCRobert Alarcón Cedeño
Robert Alarcón Cedeño
RERodrigo Estévez-Loureiro
Rodrigo Estévez-Loureiro
Mitral regurgitation is the second-most frequent valvular heart disease in Europe and it is associated with high morbidity and mortality. Recognition of MR should encourage the assessment of its etiology, severity, and mechanism in order to determine the best therapeutic approach. Mitral valve surgery constitutes the first-line therapy; however, transcatheter procedures have emerged as an alternative option to treat inoperable and high-risk surgical patients. In patients with suitable anatomy, the transcatheter edge-to-edge mitral leaflet repair is the most frequently applied procedure. In non-reparable patients, transcatheter mitral valve replacement (TMVR) has appeared as a promising intervention. Thus, currently TMVR represents a new treatment option for inoperable or high-risk patients with degenerated or failed bioprosthetic valves (valve-in-valve); failed repairs, (valve-in-ring); inoperable or high-risk patients with native mitral valve anatomy, or those with severe annular calcifications, or valve-in-mitral annular calcification. The patient selection requires multimodality imaging pre-procedural planning to select the best approach and device, study the anatomical landing zone and assess the risk of left ventricular outflow tract obstruction. In the present review, we aimed to highlight the main considerations for TMVR planning from an imaging perspective; before, during, and after TMVR.

31 January 2022 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
MBManuel Barreiro-Pérez
Manuel Barreiro-Pérez
RERodrigo Estévez-Loureiro
Rodrigo Estévez-Loureiro
RCRobert Alarcón Cedeño
Robert Alarcón Cedeño
BCBerenice Caneiro-Queija
Berenice Caneiro-Queija
JBJose Antonio Baz
Jose Antonio Baz
AIAndres Iñiguez-Romo
Andres Iñiguez-Romo

17 January 2022 in Revista Española de Cardiología (English Edition)
Verified
Journal Article
Open access
RCRobert Alarcón Cedeño
Robert Alarcón Cedeño
MBManuel Barreiro-Pérez
Manuel Barreiro-Pérez
RERodrigo Estévez-Loureiro
Rodrigo Estévez-Loureiro

1 March 2025 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
PDF file
LFLuis Mariano De la Torre Fonseca
Luis Mariano De la Torre Fonseca
RCRobert Alarcón Cedeño
Robert Alarcón Cedeño
LBLileska Andreína Hernandez Bello
Lileska Andreína Hernandez Bello
JDJuan Díaz-Heredia
Juan Díaz-Heredia
DQDiego Milton Pulla Quezada
Diego Milton Pulla Quezada
PJPablo Juan-Salvadores
Pablo Juan-Salvadores
Introdução A fenocópia de Brugada (FB) se refere a uma situação na qual os padrões eletrocardiográficos característicos da síndrome de Brugada (SB) são temporariamente manifestados, os quais são indistinguíveis dos padrões tipo 1 (coberto) e 2 (sela) da SB. Vários critérios adicionais devem ser considerados para um diagnóstico preciso. Estes incluem a presença de uma causa subjacente identificável, regressão do padrão uma vez que esta causa é corrigida, baixa probabilidade pré-teste de SB, um resultado negativo de um teste de [...] Introdução A fenocópia de Brugada (FB) se refere a uma situação na qual os padrões eletrocardiográficos característicos da síndrome de Brugada (SB) são temporariamente manifestados, os quais são indistinguíveis dos padrões tipo 1 (coberto) e 2 (sela) da SB. Vários critérios adicionais devem ser considerados para um diagnóstico preciso. Estes incluem a presença de uma causa subjacente identificável, regressão do padrão uma vez que esta causa é corrigida, baixa probabilidade pré-teste de SB, um resultado negativo de um teste de

26 November 2024 in Medicina Clinica
Verified
Journal Article
Closed access
CSCarlos Ivan Soledispa Suárez
Carlos Ivan Soledispa Suárez
RCRobert Alarcón Cedeño
Robert Alarcón Cedeño
LFLuis Mariano de la Torre Fonseca
Luis Mariano de la Torre Fonseca
SBStephanie Susana Alberca Bonilla
Stephanie Susana Alberca Bonilla
FCFabiola Loor Cedeño
Fabiola Loor Cedeño
PJPablo Juan-Salvadores
Pablo Juan-Salvadores